Adaptive Biotechnologies Corp
No enriched coverage for $ADPT in the last 7 days.
Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 adpt-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results SEATTLE, Jul. 29, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnolo
ROBINS HARLAN S (Chief Scientific Officer) sold 492,400 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $21.89 ($21.72–$22.12, $10.78M total) across 2 trades on 2026-07-21 under a Rule 10b5-1 trading plan.
Investing.com reports BTIG analyst Mark Massaro previewed seven specialty labs and diagnostics stocks as valuations rise. BTIG rates Guardant Health (GH) Buy, $190 target; Natera (NTRA) Buy, $290; BillionToOne (BLLN) Buy, $142; GeneDx (WGS) Buy, $90; Adaptive Biotechnologies (ADPT) Buy, $24; Tempus AI (TEM) Buy, $80; Caris (CAI) Buy, $32, with Q2 expectations and volume or catalyst updates.
Recent ADPT coverage spans insider activity, earnings and sector analysis.
In the last 30 days, ADPT insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($13.3M). The most active reporter was BOBULSKY SUSAN, Chief Commercial Officer, MRD, with 2 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Guidance raise plus balance-sheet actions (convertible issuance, OrbiMed repayment) and a planned MRD/Immune Medicine separation are likely to re-rate near-term growth and financing risk.
This is an insider sale under a 10b5-1 plan, which typically has limited signaling value versus discretionary selling.
The business split plan is the main valuation narrative, potentially affecting expectations for sum-of-the-parts and execution risk.
This is a routine insider open-market sale under a pre-arranged 10b5-1 plan, with limited direct signal for fundamentals.
The reverse split should mechanically reduce share count and can affect liquidity, per-share valuation, and technical levels, but it does not change underlying business fundamentals.
alphai scores every news story that mentions ADPT with an AI model for sentiment and relevance, and aggregates insider trades from Adaptive Biotechnologies Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 adpt-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results SEATTLE, Jul. 29, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnolo
6 min readROBINS HARLAN S (Chief Scientific Officer) sold 492,400 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $21.89 ($21.72–$22.12, $10.78M total) across 2 trades on 2026-07-21 under a Rule 10b5-1 trading plan.
2 min readInvesting.com reports BTIG analyst Mark Massaro previewed seven specialty labs and diagnostics stocks as valuations rise. BTIG rates Guardant Health (GH) Buy, $190 target; Natera (NTRA) Buy, $290; BillionToOne (BLLN) Buy, $142; GeneDx (WGS) Buy, $90; Adaptive Biotechnologies (ADPT) Buy, $24; Tempus AI (TEM) Buy, $80; Caris (CAI) Buy, $32, with Q2 expectations and volume or catalyst updates.
5 min readLO FRANCIS (Chief People Officer) sold 105,762 shares of Adaptive Biotechnologies Corp (ADPT) at $22.59 ($2.39M total) on 2026-07-15 under a Rule 10b5-1 trading plan.
1 min readAdaptogenics Health Corp. (CSE: ADPT) said the CSE approved a 1-for-4 share consolidation. It will take effect at the open of trading on July 15, 2026. Shares outstanding will fall from 16,397,701 to about 4,099,425, with fractional shares rounded or cancelled. Options and warrants terms will be adjusted.
1 min readAdaptive Biotechnologies said an insider sale by Robins, brother of CEO Chad Robins, involved selling over 386,000 shares for about $8.5M under a March plan, while he still holds about $21.6M. The company reported Q1 revenue up 35% to $70.9M, volume up 41%, net loss narrowing to $20M, and raised full-year MRD guidance to $260M-$270M.
5 min readROBINS HARLAN S (Chief Scientific Officer) sold 386,240 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $22.01 ($21.74–$22.45, $8.50M total) across 2 trades on 2026-07-02 under a Rule 10b5-1 trading plan.
1 min readLO FRANCIS (Chief People Officer) sold 95,842 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $22.51 ($22.18–$22.59, $2.16M total) across 3 trades over 2026-07-01 to 2026-07-02 under a Rule 10b5-1 trading plan.
2 min readBENZENO SHARON (Chief Commercial Ofc Imm Med) sold 165,802 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $21.13 ($21.00–$21.14, $3.50M total) across 2 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.
2 min readGRIFFIN MICHELLE RENEE sold 52,084 shares of Adaptive Biotechnologies Corp (ADPT) at $20.18 ($1.05M total) on 2026-06-25 under a Rule 10b5-1 trading plan.
2 min read